Notfälle
Blutspende
Karriere
Presse
Forschung
Lehre
Patienten
Zuweiser

Publikationen (2010-2017)

 

Konrad, H., Wahle, A., Altermann, W. and Schlaf, G.: Strong humoral anti-HLA immune response upon arbitrarily chosen allogeneic arterial vessels. 
J. Clin. Cell. Immunol. 8 (2017); DOI: 10.4172/2155-9899.1000525; Epub 2017 Oct 23rd

 

Goebel, S., Kehlen, A., Bluemke, K., Altermann, W., Schlaf, G., Fischer, K., Fornara, P., Wullich, B., Wach, S and Taubert H.: Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls.
Cancer Immunol. Immunother. (2017); DOI 10.1007/s00262-017-1957-3; Epub 2017 Febr 9th

 

Schlaf, G. and Altermann, W.: Basiliximab: Well-established as an immunosuppressive therapeutic antibody, but falsifying the outcome of lymphocytotoxicity-based standard cross-matching.
Buchbeitrag in: Basiliximab: Indications, Contraindications and adverse effects. Editor: Leon V. Berhardt, Chapter 5 / ID 45615 (2017): 96-113, NOVA Science Publishers Inc., New York, USA 

 

Schlaf, G., Rothhoff, A. and Altermann, W.: Der Festphasen-Kreuztest als valides diagnostisches Werkzeug zum Nachweis falsch positiver Kreuztestresultate bei Patienten mit begleitenden Autoimmunerkrankungen [Solid phase-based cross-matching as a valid tool to detect false positive CDC-based crossmatch results in recipients with accompanying autoimmune diseases].
Transfusionsmedizin 6 (2016): 169-173 (DOI 10.1055/s-0042-114209)

 

ELISA-based cross-matching allowing the detection of emerging donor-specific anti-HLA antibodies through the use of stored donors‘ cell lysates; Schlaf G, Stöhr K, Rothhoff A, Altermann W; Case Rep. Transplant.; 2015; 763157; Epub 2015 Oct 15th

 

Detection of post-transplant anti-HLA donor-specific antibodies through the use of stored donors’ cell lysates and solid phase-based cross-matching; Schlaf G, Pistorius I, Altermann W; J. Clin. Cell. Immunol.; 2015; 6; 383-391

 

Solid phase-based cross-matching in order to avoid kidney allografting against donor-specific anti-HLA antibodies: Long term experience with a procedure allowing highly reliable diagnoses; Schlaf G, Pollok-Kopp B, Altermann W; Austin J. Nephrol. Hypertens.; 2014, 1(6); Epub November 2014, Printversion folgt

 

Solid phase-based cross-matching as solution for kidney allograft recipients pretreated with therapeutic antibodies; Schlaf G, Apel S, Wahle A, Altermann W; BioMed Res. Int.; 2014; Epub September 2014, Printversion folgt

 

Systemic Lupus Erythematosus leading to terminal renal failure and excluding patients from kidney allocation due to inadequate CDC-based cross-matching: Is there a way out?; Schlaf G, Rothhoff A, Altermann W; J. Clin. Cell. Immunol.; 2014; Epub März 2014, Printversion folgt

 

Sensitive solid-phase detection of donor-specific antibodies as an aid highly relevant to improving allograft outcomes; Schlaf G, Pollok-Kopp B, Altermann W; Mol. Diagn. Ther.; 2014, 18, 185

Individual composition of human leukocyte antigens and periodontopathogens in the background of periodontitis; Reichert S, Altermann W, Stein JM, Schaller HG, Machulla HK, Schulz S; J Periodontol.; 2013, 84, 100

Artificially positive crossmatches not leading to the refusal of kidney donations due to the usage of adequate diagnostic tools; Schlaf G, Pollok-Kopp B, Schabel E, Altermann W; Case Rep. Transplant.; Epub April 2013, Printversion folgt

Buchbeitrag: „Improved detection of donor-specific anti-HLA antibodies and increased reliability of pre- and post-transplant cross-matching relevant for organ allograft survival through the use of novel solid phase-based assays” Schlaf G, Pollok-Kopp B, Altermann W als Kapitel für das Buch “Organ Donation and Organ Donors: Issues, Challenges and Perspectives”; Editor Reza F. Saidi, Nova Science Publishers, Inc., New York, USA; Buchedition im Jahr 2013

Hodgkin’s lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses; Winkler C, Steingrube DS, Altermann W, Schlaf G, Max D, Kewitz S, Emmer A, Kornhuber M, Banning-Eichenseer U, Staege MS; Cancer Immunol. Immunother. 2012, 61, 1769

General isufficiency of the classical CDC-based crossmatch to detect donor-specific anti-HLA antibodies leading to invalid results under recipients’ medical treatment or underlying diseases; Schlaf G, Mauz-Körholz C, Ott U, Leike S, Altermann W; Histol. Histopathol.; 2012, 27, 31

Generation of donor-specific anti-HLA antibodies after the transplantation of a fully-matched kidney allograft. Impact on the selection of a subsequent renal regraft: A case report; Schlaf G, Radam C, Wahle A, Altermann W; Transplant. Proc.; 2012, 381, 23 A novel ELISA-based crossmatch procedure to detect donor-specific anti-HLA antibodies responsible for corneal allograft rejections; Sel S/Schlaf G, Schurat O, Altermann W; J. Immunol. Methods; 2012, 381, 23 

Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and post-transplant crossmatching; Schlaf G, Pollok-Kopp B, Manzke T, Schurat O, Altermann W; Nephrol. Dial. Transplant. PLUS; 2010, 3, 527

HLA-Labor

Leitung:
Dr. med. W. Altermann
PD Dr. rer. nat. G. Schlaf

Annahme & HLA-Typisierung
Telefon: (0345) 557-1456 

anti-HLA Antikörper-Diagnostik
Telefon: (0345) 557-1456
Telefax: (0345) 557-1849

Standort:
Ernst-Grube-Straße 40, Komplement, 3. Ebene